Research To Practice | Oncology Videos

Featuring perspectives from Drs Justin Gainor, Corey Langer, Luis Paz‑Ares, Heather Wakelee, Jared Weiss and Helena Yu, including the following topics: Introduction (0:00) Incorporation of immunotherapeutic strategies into the management of nonmetastatic non-small cell lung cancer (NSCLC) — Heather Wakelee, MD (3:18) Contemporary treatment for localized and metastatic NSCLC with EGFR mutations — Helena Yu, MD (33:46) Research advances shaping the current and future treatment of metastatic NSCLC with ALK rearrangements, ROS1 rearrangements or RET fusions — Justin F Gainor, MD (58:03) Targeting alterations in MET, HER2, KRAS and other oncogenes in NSCLC — Jared Weiss, MD (1:19:24) Current and future management of metastatic NSCLC without a targetable tumor mutation — Corey J Langer, MD (1:42:57) Current treatment paradigm for small cell lung cancer — Luis Paz-Ares, MD, PhD (2:07:58) CME information and select publications

Featuring a slide presentation and related discussion from Dr Loretta Nastoupil, including the following topics: Current and emerging therapies for patients with follicular lymphoma (FL) (0:00) CAR (chimeric antigen receptor) T-cell therapy for patients with FL (10:34) Efficacy and tolerability of bispecific antibodies for patients with FL (19:6) CME information and select publications

Featuring an interview with Dr Loretta Nastoupil, including the following topics: Impact of COVID-19 on the management of follicular lymphoma (FL) (0:00) Case: A woman in her late 50s with Grade IIIA symptomatic FL (3:48) Case: A man in his early 70s with low-grade FL and asymptomatic adenopathy 6 years after a complete response (8:21) Case: A patient with heavily pretreated relapsed/refractory FL who received copanlisib followed by CAR (chimeric antigen receptor) T-cell therapy (14:56) Case: A woman in her early 50s with refractory FL who received mosunetuzumab (18:06) Novel treatment strategies for FL and considerations for the future (23:28) CME information and select publications

Featuring perspectives from Drs Yohann Loriot, Elizabeth Plimack and Jonathan Rosenberg, including the following topics: Introduction (0:00) Current and Future Management of Localized Urothelial Bladder Cancer (UBC) (2:59) First-Line Treatment for Patients with Metastatic UBC (mUBC) (28:29) Later-Line Therapeutic Options for Patients with mUBC: Novel Investigational Strategies (47:08) CME information and select publications

Featuring perspectives from Drs Ian Flinn, Brian Hill, John Leonard, Matthew Lunning, Laurie Sehn and Mitchell Smith, including the following topics: Introduction (0:00) Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Ian W Flinn, MD, PhD (3:07) Relapsed/Refractory CLL; Novel Investigational Strategies — Mitchell R Smith, MD, PhD (32:31) Treatment for Follicular Lymphoma — John P Leonard, MD (57:24) Management of Mantle Cell Lymphoma — Matthew Lunning, DO (1:21:22) Caring for Patients with Diffuse Large B-Cell Lymphoma — Laurie H Sehn, MD, MPH (1:44:40) Chimeric Antigen Receptor T-Cell Therapy — Brian T Hill, MD, PhD (2:10:26) CME information and select publications

Featuring perspectives from Drs Javier Cortés, Matthew Goetz, Erika Hamilton, Ian Krop, Hope Rugo and Sara Tolaney, including the following topics: Introduction (0:00) Optimizing the Management of ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (7:50) New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Erika Hamilton, MD (38:35) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (56:03) Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Javier Cortés, MD, PhD (1:18:47) Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Hope S Rugo, MD (1:40:41) Recent Advances in the Care of Patients with Metastatic TNBC — Sara M Tolaney, MD, MPH (2:11:40) CME information and select publications

Featuring perspectives from Drs Tanios Bekaii-Saab, Kristen Ciombor, Eileen O'Reilly, Philip Philip, John Strickler and Prof Eric Van Cutsem, including the following topics: Introduction (0:00) Integration of targeted therapy and immunotherapy into the management of metastatic colorectal cancer — Kristen K Ciombor, MD, MSCI (3:15) Other considerations in the management of early and advanced colorectal cancer — John Strickler, MD (33:15) Current and future treatment paradigm for gastroesophageal cancers — Eric Van Cutsem, MD, PhD (55:26) Selection and sequencing of therapy for advanced hepatocellular carcinoma — Philip A Philip, MD, PhD, FRCP (1:23:00) Novel treatment strategies for advanced biliary tract cancers — Tanios Bekaii-Saab, MD (1:50:31) CME information and select publications

Featuring perspectives from Ms Paula Anastasia, Dr Robert Coleman, Dr David O'Malley and Ms Jaclyn Shaver, including the following topics: Introduction (0:00) Management of Endometrial Cancer (5:32) Treatment for Cervical Cancer (45:31) COVID-19: Considerations in Cervical and Endometrial Cancer (1:22:34) Oncology 2032 Crystal Ball (1:27:43) CME information and select publications

Featuring perspectives from Drs Antonio González-Martín, Joyce Liu and Kathleen Moore, including the following topics: Introduction (0:00) Clinical Management of Advanced Ovarian Cancer (2:23) Novel Treatments and Strategies Under Investigation (46:04) CME information and select publications

Featuring perspectives from Drs Andrew Armstrong, Alan Bryce and Alicia Morgans, including the following topics: Introduction (0:00) Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29) Case: A woman in her late 60s with primary MF who experiences disease progression after 3 years of ruxolitinib — Jeanne Palmer, MD (17:19) Case: A woman in her late 60s with disease progression after multiple regimens for post-polycythemia vera MF — Neil Morganstein, MD (30:51) A woman in her late 70s with post-PV MF with a JAK2 V617F mutation and transfusion dependence — Bhavana (Tina) Bhatnagar, DO (39:33) Case: A man in his mid 60s with primary MF with a JAK2 mutation and recurrent herpes zoster reactivation on ruxolitinib — Niyati A Nathwani, MD (50:23) Case: A man in his early 70s with prefibrotic primary MF with a JAK2 mutation and ruxolitinib-associated HPV reactivation — Susannah Friemel, MD (53:36) Case: A man in his early 20s with myeloproliferative neoplasm with a JAK2 V617F mutation and thrombocytosis — Rajni Sinha, MD, MRCP (57:16) CME information and select publications

Featuring perspectives from Prof Harry Yoon, including the following topics: Introduction (0:00) Case: A woman in her late 30s with Stage IIIA HER2-negative adenocarcinoma of the gastric antrum (pMMR, PD-L1 CPS Case: A man in his mid 70s with metastatic esophageal adenocarcinoma (PD-L1 CPS 5) — Gurveen Kaur, MD (16:01) Case: A man in his mid 70s with HER2-negative gastroesophageal junction adenocarcinoma with multiple brain metastases (microsatellite stable, PD-L1 CPS 10) — Neil Morganstein, MD (29:00) Case: A man in his early 60s with HER2-positive esophageal adenocarcinoma (PD-L1 70%) — Kapisthalam (KS) Kumar, MD (42:19) Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (49:37) CME information and select publications

Featuring perspectives from Drs Courtney DiNardo, Michael Savona and Eunice Wang, including the following topics: Introduction (0:00) Selection of therapy for older and younger patients with acute myeloid leukemia (AML) (2:05) Therapy for patients with AML with targetable mutations (33:42) Current and future management of myelodysplastic syndromes (49:04) CME information and select publications

Featuring perspectives from Dr Kristen Ciombor and Ms Jessica Mitchell, including the following topics: Introduction (0:00) Management of localized disease (10:56) Management of HER2-negative metastatic disease (34:36) Management of HER2-positive metastatic disease (57:08) NCPD information and select publications

Featuring perspectives from Dr John Mascarenhas, including the following topics: Introduction (0:00) Case: A man in his mid 60s with post-PV myelofibrosis (MF) and ASXL1 and SRSF2 mutations — Jeanne Palmer, MD (22:40) Case: A woman in her early 70s with high-risk primary MF and a CALR mutation (28:34) Case: A woman in her mid 70s with primary MF with a JAK2 V617F mutation — Bhavana (Tina) Bhatnagar, DO (40:24) Case: A woman in her early 50s with secondary MF with a JAK2 mutation — G Richard Polkinghorn, MD (43:30) Case: A woman in her mid 80s with primary MF with an MPL mutation — Warren S Brenner, MD (47:01) Case: A woman in her mid 80s with JAK2 mutation-positive primary MF with ASXL1 and U2F2 mutations with severe anemia — Neil Morganstein, MD (53:01) Case: A woman in her mid 80s with MF with a JAK2 mutation and severe anemia — Paul Markowski, MD (56:44) CME information and select publications

Featuring perspectives from Ms Lesley Camille Ballance, Ms Amy Goodrich, Dr Lowell Hart and Dr Anthony Mato, including the following topics: Introduction (0:00) Overview of Chronic Lymphocytic Leukemia (5:47) Bruton Tyrosine Kinase Inhibitors (27:40) Venetoclax and Anti-CD20 Antibody Therapy (58:59) Future Strategies (1:15:51) NCPD information and select publications

Featuring perspectives from Ms Monica Averia, Dr Shilpa Gupta, Ms Brenda Martone and Dr Sumanta Kumar Pal, including the following topics: Introduction (0:00) Management of Localized Urothelial Bladder Cancer (UBC): Adjuvant Treatment, TAR-200 (6:47) Management of Metastatic UBC: Antibody-Drug Conjugates, Checkpoint Inhibitors (33:00) Management of UBC with an FGFR Mutation (57:37) Oncology/UBC 2032 and a Crystal Ball (1:19:52) NCPD information and select publications

Featuring perspectives from Ms Ilene Galinsky and Dr Eunice Wang, including the following topics: Introduction (0:00) Younger patients with acute myeloid leukemia (AML) (2:11) Older patients with AML (34:45) Treatment for myelodysplastic syndromes (49:57) NCPD information and select publications

Featuring perspectives from Dr Susan O'Brien, including the following topics: Introduction (0:00) Case: A woman in her mid 60s with relapsed Chronic Lymphocytic Leukemia (CLL) who experiences severe headaches on acalabrutinib — Bhavana (Tina) Bhatnagar, DO (12:57) Case: A man in his early 70s with IGHV-unmutated relapsed CLL — Gurveen Kaur, MD (24:43) Case: A man in his late 60s with chronic kidney disease and CLL who develops metastatic rectal cancer while receiving acalabrutinib — G Richard Polkinghorn, MD (31:11) Case: A woman in her mid 60s with relapsed CLL suspicious for Richter's transformation; Del(13q), TP53 and BTK resistance mutation — John N Allan, MD (35:18) Case: A woman in her mid 20s with CLL and transfusion-dependent autoimmune myelofibrosis — Amanda Blackmon, DO, MS (48:47) Journal Club with Susan O'Brien, MD (53:07) CME information and select publications

Featuring perspectives from Ms Marianne Davies, Dr Matthew Gubens, Dr Lowell Hart and Ms Chaely Medley, including the following topics: Introduction (0:00) Overview of Small Cell Lung Cancer (SCLC) (6:42) First-line Therapy and Prevention of Cytopenias (25:03) Second Line and Beyond (1:04:33) SVC (Superior Vena Cava), SIADH (Syndrome of Inappropriate Antidiuretic Hormone) and Other Paraneoplastic Syndromes (1:20:25) Complementary Treatments (1:25:57) NCPD information and select publications

Featuring perspectives from Dr Richard Finn and Ms Amanda Wagner, including the following topics: Introduction (0:00) First-line Treatment of Hepatocellular Cancer (HCC) (2:28) Management of Recurrent HCC (26:57) Treatment of Biliary Tract Cancers (33:39) NCPD information and select publications

Featuring a slide presentation and related discussion from Dr Brian Rini on the role of immunotherapy in nonmetastatic renal cell carcinoma and considerations for disease management in special patient populations. CME information and select publications

Featuring perspectives from Drs Thomas Hutson and Brian Rini, including the following topics: Introduction — Common Questions in the Management of Renal Cell Carcinoma (0:00) Adjuvant Immunotherapy (11:26) First-Line Treatment of Metastatic Disease (27:00) Management of Relapsed/Refractory Disease (38:25) Treatment with Belzutifan (47:35) CME information and select publications

A clinical investigator think tank and enduring multimedia activity with Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang, including the following topics: Introduction to therapy-related Acute Myeloid Leukemia (AML) (0:00) Treatment of AML evolving from prior MDS (12:27) Treatment of secondary AML in a patient ineligible for intensive therapy (29:41) Treatment for a patient with secondary AML with an IDH mutation (40:56) Long-term follow-up of CPX- 351 in patients with secondary AML (46:27) Potential role of venetoclax in combination with intensive chemotherapy regimens (52:54) Treatment for younger patients with secondary AML (58:46) Treatment of secondary AML with a FLT3 mutation (1:03:59) Data with CPX-351 in combination with targeted agents (1:08:30) Refractory disease versus differentiation syndrome from IDH inhibitors (1:19:20) Emerging data with menin inhibitors (1:28:13) Treatment of secondary AML evolving from prior MPN (1:31:52) Treatment of secondary AML with core binding factor (1:53:14) CME information and select publications

Featuring perspectives from Drs Raoul Concepcion, Fred Saad and Matthew Smith, moderated by Dr Emmanuel Antonarakis, including the following topics: Introduction (0:00) Management Approaches for Nonmetastatic Prostate Cancer — Raoul S Concepcion, MD (3:00) Role of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer — Matthew R Smith, MD, PhD (31:55) Selection and Sequencing of Therapy for Metastatic Castration-Resistant Prostate Cancer — Emmanuel S Antonarakis, MD (1:00:03) Current and Future Integration of PARP Inhibitors in the Management of Prostate Cancer — Fred Saad, MD (1:30:29) CME information and select publications

Featuring perspectives from Dr Justin Gainor, including the following topics: Introduction (0:00) Immunotherapy for Patients with Targetable Mutations (8:02) Case: A man in his early 80s with recurrent, localized spindle cell carcinoma of the lung, PD-L1 of 40% — Kapisthalam (KS) Kumar, MD (16:03) Case: A woman in her late 50s with microsatellite-stable adenocarcinoma of the lung with an NRG1 fusion — Ranju Gupta, MD (26:57) Case: A woman in her late 50s with metastatic PD-L1-negative adenocarcinoma of the lung and a RET KF5B fusion — Neil Morganstein, MD (32:13) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an ALK rearrangement, PD-L1 of 5% — Susannah Friemel, MD (37:17) Cases: A woman in her early 50s with metastatic NSCLC and an ALK (2p23) rearrangement, PD-L1 tumor proportion score of 50%; a man in his mid 60s with metastatic adenocarcinoma of the lung involving the brain, an ALK rearrangement and PD-L1 of 20% — Daniel R Carrizosa, MD, MS (41:52) Case: A man in his late 60s with metastatic adenocarcinoma of the lung and a HER2 V659D mutation — Spencer Henick Bachow, MD (47:49) CME information and select publications

Featuring perspectives from Drs Matthew Galsky, Ashish Kamat and Stephen Williams, moderated by Dr Sumanta Kumar Pal, including the following topics: Introduction (0:00) Available Data with and Ongoing Investigation of Novel Agents and Strategies for Non-Muscle-Invasive Bladder Cancer (NMIBC) — Ashish M Kamat, MD, MBBS (2:17) Novel Therapeutic Approaches for Muscle-Invasive Bladder Cancer (MIBC) — Stephen B Williams, MD, MS (33:41) Current and Future Front-Line Management of Metastatic Urothelial Bladder Carcinoma (mUBC) — Matthew D Galsky, MD (1:00:55) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Sumanta Kumar Pal, MD (1:43:07) CME information and select publications

Featuring perspectives from Ms Jennifer Filipi, Dr Kathleen Moore, Dr Krishnansu Tewari and Ms Deborah Wright, including the following topics: Introduction (0:00) Primary Ovarian Cancer: Neoadjuvant and Adjuvant Chemotherapy (11:48) PARP Inhibitor Maintenance Therapy (29:29) Adherence in the Maintenance Setting (1:02:06) Novel Strategies and Clinical Trials (1:15:55) NCPD information and select publications

Featuring perspectives from Dr Yelena Janjigian, including the following topics: Introduction (0:00) Management of HER2-Negative Gastroesophageal Cancers (2:10) Case: A man in his early 60s with HER2-negative metastatic squamous cell carcinoma of the esophagus; PD-L1 70% — Kapisthalam (KS) Kumar, MD (23:56) Case: A man in his late 50s with a history of GERD diagnosed with localized esophageal adenocarcinoma — Gurveen Kaur, MD (26:43) Case: A man in his early 50s with localized gastroesophageal-junction adenocarcinoma — G Richard Polkinghorn, MD (30:05) Case: A man in his early 80s with localized HER2-negative esophageal adenocarcinoma — Raymond Lobins, DO (33:24) Case: A man in his early 80s with HER2-negative metastatic gastric cancer; MSS, PD-L1 CPS 5 — Neil Morganstein, MD (35:44) Treatment for HER2-Positive Gastroesophageal Cancers (44:34) Case: A woman in her mid 60s with metastatic esophageal adenocarcinoma; PD-L1 CPS 5, HER2 amplification — Dr Kaur (49:58) Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (53:44) Journal Club with Dr Janjigian (57:37) CME information and select publications

Featuring perspectives from Dr Edward Garon, Ms Kelly Goodwin, Ms Tara Plues and Dr Anne Tsao, including the following topics: Introduction (0:00) Key Lung Cancer Diagnostic Tools (7:40) Targeted Therapy for Localized Disease (18:05) Targeted Therapy for Metastatic Disease (33:01) Immunotherapy for Localized Disease (1:31:18) Immunotherapy for Metastatic Disease (1:53:36) NCPD information and select publications

Featuring perspectives from Ms Jamie Carroll, Dr Sara Hurvitz, Ms Kelly Leonard and Dr Hope Rugo, including the following topics: Introduction (0:00) High-Risk Localized ER-Positive, HER2-Negative Breast Cancer (5:07) ER-Positive Metastatic Breast Cancer (28:06) Localized HER2-Positive Breast Cancer (49:15) Metastatic HER2-Positive Breast Cancer (1:07:06) Localized Triple-Negative Breast Cancer (TNBC); Role of Immunotherapy (1:30:08) Metastatic TNBC (1:49:41) CME information and select publications

Featuring perspectives from Ms Kathy Burns, Dr Robert Dreicer, Dr Sandy Srinivas and Mr Ronald Stein, including the following topics: Introduction (0:00) PSA-Only Recurrence (M0 Disease) (10:45) Metastatic Hormone-Sensitive Prostate Cancer (35:07) Metastatic Castration-Resistant Prostate Cancer (BRCA Wild Type) (48:48) Metastatic Castration-Resistant Prostate Cancer (BRCA Mutant) (1:10:42) CME information and select publications